Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B
A Phase 1/2, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-2218
Sponsor: Alnylam Pharmaceuticals
Listed as NCT03672188, this PHASE1/PHASE2 trial focuses on Chronic Hepatitis B and remains completed. Sponsored by Alnylam Pharmaceuticals, it has been updated 12 times since 2018, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Nov 2021 — Jan 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 7 earlier versions
-
Sep 2021 — Nov 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2019 — Jul 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2019 — Jun 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2018 — Apr 2019 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2018 — Dec 2018 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Alnylam Pharmaceuticals
- Vir Biotechnology, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .